What this study is
Unblinded, controlled, non-randomized, mechanistic study to determine whether physiological mechanisms underlying PVC are sensitive to adenosine. One hundred subjects undergoing clinically-indicated, standard-of-care cardiac electrophysiology study (EPS) procedure for PVCs will receive adenosine and/or verapamil to learn if their arrhythmias are inducible similarly to sustained ventricular tachycardia.
What's being tested
- Adenosine
Intervention · DRUG
Adenosine: 0.84 mg/kg (140 mcg/kg/minute IV for 6 minutes) Verapamil 0.15 mg/kg
Study details
- Sponsor
- Weill Medical College of Cornell University
- Conditions
- Premature Ventricular Contraction (PVC)
- Enrolling
- 100 people
- Starts
- 2017-02-13
- Est. completion
- 2025-12-31
- Design
- Open-label, single group, Phase 4
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 70 YearsSex ALLHealthy volunteers AcceptedYou may qualify if
- Diagnosis of premature ventricular contractions (PVCs)
- Scheduled to undergo an electrophysiology study with the intention of performing cardiac ablation for the treatment of PVCs
- Male or female between the ages of 18 and 70 years
- Capable of giving informed consent
You can't join if
- Any structural heart disease
- Coronary artery disease (≥ 70% stenosis)
- Current treatment with anti-arrhythmic drugs
- Pregnant
- Asthma (if administering adenosine)
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openWeill Cornell Medicine
New York, New York, United States
- Dolores T Reynolds, BSN · Contact212 746 4617dtr2001@med.cornell.edu
- James E Ip, M.D · Contact212 746 2158jei9008@med.cornell.edu
Recruiting
Study team
Sponsor
Weill Medical College of Cornell University
Study ID 1609017561
Principal investigator
James E Ip, M.D
Weill Medical College of Cornell University
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.